Filtered By:
Drug: Vytorin
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 591 results found since Jan 2013.
Emerging therapies in dyslipidaemias
Vascul Pharmacol. 2023 Sep 14:107229. doi: 10.1016/j.vph.2023.107229. Online ahead of print.ABSTRACTSeveral observations have shown that elevated levels of low-density lipoprotein cholesterol (LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for reducing cardiovascular risk, with a continuous linear correlation between LDL-C reduction and cardiovascular benefit. Based on these observations, current guidelines have further lowered LDL-C goals and call for the use of more effective therapeutic interventions. In addition to statins, ezetimibe and the monoclonal antibodies targeting PCSK9, several...
Source: Vascular Pharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Alberico L Catapano Source Type: research
Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease
In this study, we aimed to examine the variability in plasma lipids under two different lipid-lowering regimens (intensive statin therapy versus the combination of conventional-dose statins with ezetimibe). In total, we have retrospectively examined 1275 patients with CAD from January 2009 to April 2019 and divided them into two groups: intensive statin group and conventional-dose statins combined with ezetimibe group. All patients were followed up for at least 1 year. Lipid variability was verified by standard deviation (SD), coefficient of variation (CV), and variability independent of mean (VIM) triple methods. Multiple...
Source: Atherosclerosis - September 13, 2023 Category: Cardiology Authors: Jinhua Jin Liwen Shan Manjun Wang Lu Liu Tian Xu Duanbin Li Zhezhe Chen Xianglan Liu Wenbin Zhang Ya Li Source Type: research
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry
CONCLUSION: Approximately 2 years after publication of the guidelines, LDL-C and non-HDL-C goal attainment was rarely achieved in patients with T1D and T2D with a high or very high cardiovascular risk.PMID:37694759 | DOI:10.1111/dom.15264
Source: Atherosclerosis - September 11, 2023 Category: Cardiology Authors: Julia Brandts Sascha R Tittel Peter Bramlage Thomas Danne Johanna M Brix Stefan Zimny Christoph H J Heyer Reinhard W Holl Dirk M üller-Wieland Source Type: research
Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment
CONCLUSION: AT combined with EZ can effectively improve glucose, lipids, inflammation and upregulate serum bilirubin in patients with HY combined with T2DM.PMID:37632947
Source: Alternative Therapies in Health and Medicine - August 26, 2023 Category: Complementary Medicine Authors: Siyu Zhu Tehasi Wang Qingyi Wang Mengyu Du Source Type: research
HDL abnormalities in type 2 diabetes: Clinical implications
Atherosclerosis. 2023 Aug 3:117213. doi: 10.1016/j.atherosclerosis.2023.117213. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD) represents the primary cause of mortality among patients with Type 2 Diabetes Mellitus (T2DM). In this population, High-Density Lipoprotein (HDL) particles exhibit abnormalities in number, composition, and function, culminating in diminished anti-atherosclerotic capabilities despite normal HDL cholesterol (HDL-C) concentrations. Hyperglycemic conditions contribute to these alterations in HDL kinetics, composition, and function, causing T2DM patients' HDL particles to e...
Source: Atherosclerosis - August 14, 2023 Category: Cardiology Authors: Alexandro J Martagon Rafael Zubir án Rogelio Gonz ález-Arellanes Samantha Praget-Bracamontes J Adri án Rivera-Alcántara Carlos A Aguilar-Salinas Source Type: research
Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study
Lancet Reg Health Eur. 2023 Jun 8;31:100665. doi: 10.1016/j.lanepe.2023.100665. eCollection 2023 Aug.ABSTRACTBACKGROUND: The impact of the stepwise implementation of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) treatment algorithm on low-density lipoprotein cholesterol (LDL-C) goal attainment was simulated in patients from the DA VINCI study.METHODS: Monte Carlo simulation was used to evaluate treatment optimisation scenarios, based on a patient's risk category: statin intensification (step 1), addition of ezetimibe (step 2), and addition of a proprotein convertase subtilisin/kexin t...
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Julia Brandts Sarah Bray Guillermo Villa Alberico L Catapano Neil R Poulter Antonio J Vallejo-Vaz Kausik K Ray DA VINCI study group Source Type: research
Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study
CONCLUSION: In Austria, patients were initiated on evolocumab at LDL‑C levels almost 3‑times higher than the guideline-recommended clinical goal (< 55 mg/dL). Persistence with evolocumab was very high. Evolocumab led to a rapid and sustained LDL‑C reduction with 65% attaining the LDL‑C goal. Patients using evolocumab in combination with statins and/or ezetimibe were more likely to attain their LDL‑C goal and thus decrease cardiovascular risk.PMID:37525072 | DOI:10.1007/s00508-023-02245-w
Source: Wiener Klinische Wochenschrift - July 31, 2023 Category: General Medicine Authors: Christoph Ebenbichler Heinz Drexel Ursula Hanusch Hermann Toplak Nafeesa N Dhalwani Ian Bridges Robert Hoelzl Margit Hemetsberger Kausik K Ray Source Type: research
Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions
Kardiol Pol. 2023 Jul 25. doi: 10.33963/KP.a2023.0162. Online ahead of print.ABSTRACTCardiovascular diseases account for 43% of deaths in Poland. The COVID-19 pandemic increased the number of cardiovascular deaths by as much as 16.7%. Lipid metabolism disorders are observed in about 20 million Poles. Lipid disorders are usually asymptomatic, they cause a significant increase in the risk of cardiovascular diseases. Up to 20% of patients who experience an acute coronary syndrome (ACS) may experience a recurrence of a cardiovascular event within a year, and up to 40% of these patients may be re-hospitalized. Within 5 years af...
Source: Polish Heart Journal - July 25, 2023 Category: Cardiology Authors: Przemys ław Mitkowski Adam Witkowski Janina St ępińska Maciej Banach Piotr Jankowski Mariusz G ąsior Krystian Wita Stanis ław Bartuś Pawe ł Burchardt Micha ł M Farkowski Marek Gierlotka Robert Gil Przemys ław Leszek Maciej Sterli ński Piotr Szym Source Type: research
